Table 5.
KEGG pathway enrichment analysis of differentially expressed miRNA target genes (top 15).
| KEGG ID | KEGG term | Count | FDR | Genes |
|---|---|---|---|---|
| hsa05200 | Pathways in cancer | 27 | 1.78E-11 | CCNE2, STAT1, KITLG, RARB, BIRC5, E2F3, EPAS1, FZD7, BMP2, NRAS, COL4A5, CDK4, NFKBIA, RAD51, WNT2, BID, FZD4, MYC, PIK3CD, ITGAV, BRCA2, ITGB1, ARNT2, ZBTB16, HDAC2, PTGS2, MMP1 |
| hsa04110 | Cell cycle | 14 | 1.48E-07 | CCNE2, ESPL1, CDC14A, GADD45A, E2F3, CHEK1, CCND2, CDK4, CDC25C, CDC6, RBL2, MYC, CDC25A, HDAC2 |
| hsa05222 | Small cell lung cancer | 11 | 9.81E-07 | CCNE2, RARB, E2F3, COL4A5, CDK4, NFKBIA, MYC, PIK3CD, ITGAV, ITGB1, PTGS2 |
| hsa04060 | Cytokine-cytokine receptor interaction | 16 | 3.08E-05 | INHBB, IL15RA, KITLG, IL15, BMP2, CXCL3, CLCF1, TNFSF15, PRLR, CCR1, GHR, CD40LG, CCL8, TNFRSF9, TNFSF4, CCR6 |
| hsa04662 | B cell receptor signaling pathway | 8 | 3.15E-04 | CD22, CD79A, NRAS, NFKBIA, LYN, PIK3CD, PPP3CA, CD19 |
| hsa05162 | Measles | 10 | 3.87E-04 | CCNE2, STAT1, EIF2AK2, TNFAIP3, CCND2, CDK4, NFKBIA, PIK3CD, OAS3, ADAR |
| hsa04115 | p53 signaling pathway | 5 | 4.14E-04 | CCNE2, GADD45A, CHEK1, CCND2, CDK4 |
| hsa04640 | Hematopoietic cell lineage | 8 | 4.18E-04 | CD22, KITLG, CD1D, TFRC, CD1C, CD19, MS4A1, CR1 |
| hsa05220 | Chronic myeloid leukemia | 7 | 6.01E-04 | E2F3, NRAS, CDK4, NFKBIA, MYC, PIK3CD, HDAC2 |
| hsa04630 | Jak-STAT signaling pathway | 10 | 7.27E-04 | IL15RA, STAT1, IL15, CCND2, CLCF1, SOCS5, PRLR, MYC, PIK3CD, GHR |
| hsa05140 | Leishmaniasis | 4 | 8.58E-04 | STAT1, NFKBIA, ITGB1, PTGS2 |
| hsa05160 | Hepatitis C | 9 | 8.98E-04 | STAT1, EIF2AK2, CLDN8, NRAS, NFKBIA, TRADD, PIK3CD, MAPK14, OAS3 |
| hsa05340 | Primary immunodeficiency | 5 | 9.13E-04 | CD79A, ADA, CD40LG, CD19, UNG |
| hsa05219 | Bladder cancer | 3 | 1.22E-03 | E2F3, CDK4, MYC |
| hsa04610 | Complement and coagulation cascades | 6 | 1.77E-03 | PLAUR, PROS1, C3AR1, C7, CR1, PLAU |
FDR – false discovery rate.